Use of checkpoint inhibitor pembrolizumab has continued to grow since its approval in 2014. Rare instances of conduction side effects have been described including brady and tachyarrhythmias, heart block and even cardiac arrest. We present a case of Pembrolizumab induced myocarditis and persistent third-degree heart block.
No takes yet. Share an insight, caveat, or question.
Adhikari et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: